Home › Steatotic Liver Disease › Florida › St. Petersburg
Steatotic Liver Disease clinical trials in St. Petersburg, FL
3 studies for Steatotic Liver Disease are looking for participants at sites in and around St. Petersburg (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
RecruitingPhase 3
- Care Access - St. Petersburg, St. Petersburg
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RecruitingPhase 3
- Akero Clinical Study Site, Bradenton · 20 mi away
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
RecruitingPhase 2
- Synergy Healthcare, Bradenton · 20 mi away
- Synergy Healthcare, Bradenton · 20 mi away
About Steatotic Liver Disease
Steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in your liver. Learn about the causes and treatments.
More about Steatotic Liver Disease on MedlinePlus
Steatotic Liver Disease trials in other cities
- San Antonio, TX17 studies
- Miami, FL16 studies
- New York City, NY16 studies
- San Diego, CA14 studies
- Houston, TX13 studies
- Austin, TX13 studies
- Richmond, VA12 studies
- Chandler, AZ10 studies
- Tucson, AZ10 studies
- Dallas, TX9 studies
- Orlando, FL9 studies
- St. Louis, MO9 studies
Other studies in St. Petersburg
- Non-Small Cell Lung Cancer21 studies
- Breast Cancer11 studies
- Obesity9 studies
- Overweight9 studies
- Colorectal Cancer8 studies
- Heart Failure8 studies
- Lung Cancer7 studies
- Endometrial Cancer6 studies
- Burkitt Lymphoma6 studies
- Ovarian Cancer6 studies
- Type 2 Diabetes5 studies
- COPD5 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.